Opinion Statement
In our armamentarium against neuroendocrine hepatic metastases, radiofrequency thermal ablation has proven to play a valuable role. Patients with neuroendocrine malignancies that progress to hepatic metastases may suffer not only from the hormonal sequelae of their disease, but also face the specter of death within several years from progressive hepatic replacement. For the majority of these patients who are not surgical candidates due to the extent of liver involvement, radiofrequency thermal ablation represents a low-risk treatment modality effective at both symptom alleviation and survival prolongation. Utilizing a laparoscopic approach guided by intra-operative ultrasound, effective tumor ablation can be achieved with minimal morbidity and low rates of local tumor recurrence.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241(5):776–783; discussion 783–785
Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197(1):29–37
Carty SE, Jensen RT, Norton JA Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112(6):1024–1031; discussion 1031–1032
Lounsberry W, Goldschmidt V, Linke C The early histologic changes following electrocoagulation. J Urol 1961; 86:291–297
Buscarini L, Rossi S, Fornari F, et al. Laparoscopic ablation of liver adenoma by radiofrequency electrocautery. Gastrointest Endosc 1995; 41(1):68–70
Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995; 1(1):73–81
Berber E, Flesher NL, Siperstein AE Initial clinical evaluation of the RITA 5-centimeter radiofrequency thermal ablation catheter in the treatment of liver tumors. Cancer J Sci Am 2000; 6(S4):S319–329
Berber E, Siperstein AE Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc 2007; 21(4):613–618
Mazzaglia PJ, Berber E, Milas M, Siperstein AE Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142(1):10–19
Berber E, Flesher N, Siperstein AE Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26(8):985–990
Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190(4):432–445
Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129(2):170–175
Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169(1):36–42; discussion 42–43
Carrasco CH, Charnsangavej C, Ajani J, et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147(1):149–154
Perry LJ, Stuart K, Stokes KR, Clouse ME Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116(6):1111–1116; discussion 1116–1117
Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long- acting somatostatin analogue. N Engl J Med 1986; 315(11):663–666
Janson ET, Oberg K Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32(2):225–229
Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39(2):279–283
Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997; 122(6):1040–1047; discussion 1047–1048
Proye CA, Lokey JS Current concepts in functioning endocrine tumors of the pancreas. World J Surg 2004; 28(12):1231–1238
Martin LW, Warren RS Current management of colorectal liver metastases. Surg Oncol Clin N Am 2000; 9(4):853–876; discussion 877–878
Carty SE, Jensen RT, Norton JA Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112(6):1024–1031; discussion 1031–1032
Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130(4):677–682; discussion 682–685
Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104(8):1590–1602
Seifert JK, Junginger T, Morris DL A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43(3):141–154
O’Toole D, Ruszniewski P Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19(4):585–594
Oberg K Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994; 5(5):503–519
Moertel CG Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5(10):1502–1522
Kvols LK, Buck M Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 1987; 82(5B):77–83
Foroutani A, Garland AM, Berber E, et al. Laparoscopic ultrasound vs. triphasic computed tomography for detecting liver tumors. Arch Surg 2000; 135(8):933–938
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mazzaglia, P.J., Berber, E. & Siperstein, A.E. Radiofrequency Thermal Ablation of Metastatic Neuroendocrine Tumors in the Liver. Curr. Treat. Options in Oncol. 8, 322–330 (2007). https://doi.org/10.1007/s11864-007-0038-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-007-0038-9